SCHEMBL1250641

SCHEMBL1250641

CCOC(=O)COc1cc(C)c(C=O)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.53
NPSR1 Q6W5P4 2/20 0.53
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 2/20 0.47
ALDH1A1 P00352 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP3A4 P08684 2/20 0.43
USP2 O75604 1/20 0.43
HPGD P15428 4/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
CYP2C9 P11712 1/20 0.43
NTSR1 P30989 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1249146 0.85 ALDH1A1 (0.48) GAAKDM4EHSD17B10ALDH1A1CYP1A2
SCHEMBL27169475 0.84 GAA (0.50) GAANPSR1KDM4EHSD17B10ALDH1A1
SCHEMBL8791845 0.81 HPGD (0.57) KDM4EHSD17B10ALDH1A1SMN1; SMN2HPGD
SCHEMBL18002539 0.81 PSEN1 (0.42) NPSR1KDM4EHSD17B10ALDH1A1CYP2C19
SCHEMBL1249132 0.81 ALDH1A1 (0.48) NPSR1KDM4EHSD17B10ALDH1A1SMN1; SMN2
SCHEMBL18183342 0.80 NLRP3 (0.48) GAANPSR1KDM4EHSD17B10ALDH1A1
SCHEMBL17281890 0.80 ALDH1A1 (0.49) GAANPSR1KDM4EHSD17B10ALDH1A1
SCHEMBL25235299 0.80 GAA (0.51) GAANPSR1KDM4EHSD17B10ALDH1A1
SCHEMBL27623217 0.80 ALDH1A1 (0.62) GAANPSR1KDM4EHSD17B10ALDH1A1
SCHEMBL8792574 0.80 OGG1 (0.44) HSD17B10ALDH1A1KMT2AHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074089-B1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-09-18 EP disclosed
US-8222248-B2 Organic compounds NOVARTIS AG (CH) 2012-07-17 US disclosed
US-20110046133-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2011-02-24 US disclosed
EP-2074089-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2009-07-01 EP disclosed
WO-2008048991-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046133-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 GAA 74/4885NPSR1 4329/4885KDM4E 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.